BPMC - Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
- CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates.
- Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will conduct trials for Link Health's in-licensed portfolio.
- Discovered by CStone's partner Blueprint Medicines, Gavreto is approved in the US and is the first approved selective RET inhibitor in China.
For further details see:
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal